JP7879131B2 - 新規の抗グレムリン１抗体 - Google Patents

新規の抗グレムリン１抗体

Info

Publication number
JP7879131B2
JP7879131B2 JP2023543120A JP2023543120A JP7879131B2 JP 7879131 B2 JP7879131 B2 JP 7879131B2 JP 2023543120 A JP2023543120 A JP 2023543120A JP 2023543120 A JP2023543120 A JP 2023543120A JP 7879131 B2 JP7879131 B2 JP 7879131B2
Authority
JP
Japan
Prior art keywords
cancer
sequence
antibody
antigen
gremlin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023543120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504124A5 (enExample
JP2024504124A (ja
Inventor
キアン，シュエミン
ツイ，スーリー
リー，ホンジュン
スン，ディー
グオ，フアンフアン
Original Assignee
スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド filed Critical スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド
Publication of JP2024504124A publication Critical patent/JP2024504124A/ja
Publication of JP2024504124A5 publication Critical patent/JP2024504124A5/ja
Application granted granted Critical
Publication of JP7879131B2 publication Critical patent/JP7879131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023543120A 2021-01-18 2022-01-17 新規の抗グレムリン１抗体 Active JP7879131B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/072397 2021-01-18
CN2021072397 2021-01-18
CN2021142043 2021-12-28
CNPCT/CN2021/142043 2021-12-28
PCT/CN2022/072297 WO2022152290A1 (en) 2021-01-18 2022-01-17 Novel anti-gremlin1 antibodies

Publications (3)

Publication Number Publication Date
JP2024504124A JP2024504124A (ja) 2024-01-30
JP2024504124A5 JP2024504124A5 (enExample) 2025-01-24
JP7879131B2 true JP7879131B2 (ja) 2026-06-23

Family

ID=82446960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543120A Active JP7879131B2 (ja) 2021-01-18 2022-01-17 新規の抗グレムリン１抗体

Country Status (10)

Country Link
US (1) US20240294622A1 (enExample)
EP (1) EP4277927A4 (enExample)
JP (1) JP7879131B2 (enExample)
KR (1) KR20230132544A (enExample)
CN (1) CN116848135A (enExample)
AU (1) AU2022207030A1 (enExample)
CA (1) CA3208455A1 (enExample)
MX (1) MX2023008423A (enExample)
TW (1) TW202241944A (enExample)
WO (1) WO2022152290A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230156936A (ko) * 2021-03-11 2023-11-15 상하이 지아오통 대학 그렘린1 길항제를 사용하여 질환을 치료하는 방법
GB202205203D0 (en) * 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) * 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
KR20250169623A (ko) * 2023-04-13 2025-12-03 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 암 치료를 위한 grem1 길항제를 수반하는 조합 요법
TW202541848A (zh) * 2024-01-08 2025-11-01 中國大陸商蘇州創勝醫藥集團有限公司 用於治療ｐａｈ之ｇｒｅｍ１拮抗劑及活化素受體拮抗劑的組合療法
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512894A (ja) 2012-03-15 2015-04-30 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
JP2016519650A (ja) 2013-03-14 2016-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト抗ｇｒｅｍ１抗体
JP2019529371A (ja) 2016-08-29 2019-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 肺動脈性肺高血圧を処置するための抗グレムリン−１（ｇｒｅｍ１）抗体およびその使用の方法
WO2019243801A1 (en) 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
JP2020511946A (ja) 2016-12-19 2020-04-23 ユーシービー バイオファルマ エスアールエル グレムリン−１の結晶構造及び阻害抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230156936A (ko) * 2021-03-11 2023-11-15 상하이 지아오통 대학 그렘린1 길항제를 사용하여 질환을 치료하는 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512894A (ja) 2012-03-15 2015-04-30 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
JP2016519650A (ja) 2013-03-14 2016-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト抗ｇｒｅｍ１抗体
JP2019529371A (ja) 2016-08-29 2019-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 肺動脈性肺高血圧を処置するための抗グレムリン−１（ｇｒｅｍ１）抗体およびその使用の方法
JP2020511946A (ja) 2016-12-19 2020-04-23 ユーシービー バイオファルマ エスアールエル グレムリン−１の結晶構造及び阻害抗体
WO2019243801A1 (en) 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLoS ONE，2012年，Vol. 7, Issue 4, e35100，pp. 1-8，doi: 10.1371/journal.pone.0035100

Also Published As

Publication number Publication date
JP2024504124A (ja) 2024-01-30
CA3208455A1 (en) 2022-07-21
MX2023008423A (es) 2023-07-26
US20240294622A1 (en) 2024-09-05
EP4277927A1 (en) 2023-11-22
EP4277927A4 (en) 2025-07-23
AU2022207030A9 (en) 2024-09-19
AU2022207030A1 (en) 2023-08-24
TW202241944A (zh) 2022-11-01
KR20230132544A (ko) 2023-09-15
CN116848135A (zh) 2023-10-03
WO2022152290A1 (en) 2022-07-21

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260611

R150 Certificate of patent or registration of utility model

Ref document number: 7879131

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150